Krystal Biotech (KRYS) is moving from the S&P SmallCap 600 to the S&P MidCap 400 as part of the July 24, 2026 rebalance. Berkshire Hathaway’s acquisition of Taylor Morrison triggers the KRYS MidCap inclusion and TMHC removal, while V2X and Tutor Perini enter/exit the SmallCap 600. The shift could lift KRYS liquidity and passive inflows around the event.
Index inclusions often trigger passive fund buying and improved liquidity. KRYS’s move to MidCap 400 can attract index-tracking inflows, potentially narrowing bid-ask spreads and increasing institutional ownership over weeks after the rebalance. Historical examples show modest near-term upside for name changes tied to index rebalances, with longer-term prospects tied to growth and fundamentals.
KRYS should see modest near-term upside from index inclusion and liquidity gains around the July 24 rebalance.
Category Type: Industry News. This is a benchmark index rebalance event that affects KRYS's classification, liquidity, and potential passive inflows, typical of large-cap/mid-cap reclassifications.